Table of Contents Author Guidelines Submit a Manuscript
International Journal of Rheumatology
Volume 2015, Article ID 276815, 9 pages
http://dx.doi.org/10.1155/2015/276815
Research Article

Serum Markers in Rheumatoid Arthritis: A Longitudinal Study of Patients Undergoing Infliximab Treatment

1Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, 5020 Bergen, Norway
2Department of Rheumatology, Haukeland University Hospital, University of Bergen, 5020 Bergen, Norway

Received 18 September 2015; Revised 30 October 2015; Accepted 30 November 2015

Academic Editor: Bruce M. Rothschild

Copyright © 2015 Oddgeir Selaas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. S. Gulko and R. J. Winchester, “Rheumatoid arthitis,” in Samter's Immunologic Diseases, K. F. Austen, M. M. Frank, J. P. Atkinson, and H. Cantor, Eds., chapter 37, pp. 427–463, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 6th edition, 2001. View at Google Scholar
  2. A. L. M. A. Jansen, I. E. van der Horst-Bruinsma, D. van Schaardenburg, R. J. van de Stadt, M. H. M. T. de Koning, and B. A. C. Dijkmans, “Rheumatoid factor and antibodies to cyclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis,” Journal of Rheumatology, vol. 29, no. 10, pp. 2074–2076, 2002. View at Google Scholar · View at Scopus
  3. A. Kastbom, G. Strandberg, A. Lindroos, and T. Skogh, “Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project),” Annals of the Rheumatic Diseases, vol. 63, no. 9, pp. 1085–1089, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. I. K. Gao, A. Haas-Wöhrle, K. G. Mueller, H.-M. Lorenz, and C. Fiehn, “Determination of anti-CCP antibodies in patients with suspected rheumatoid arthritis: does it help to predict the diagnosis before referral to a rheumatologist?” Annals of the Rheumatic Diseases, vol. 64, no. 10, pp. 1516–1517, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. M. L. L. Prevoo, M. A. van'T Hof, H. H. Kuper, M. A. van Leeuwen, L. B. A. van De Putte, and P. L. C. M. van Riel, “Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis,” Arthritis & Rheumatism, vol. 38, no. 1, pp. 44–48, 1995. View at Publisher · View at Google Scholar · View at Scopus
  6. J. S. Smolen, F. C. Breedveld, M. H. Schiff et al., “A simplified disease activity index for rheumatoid arthritis for use in clinical practice,” Rheumatology, vol. 42, no. 2, pp. 244–257, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. Y. Yazici and I. Simsek, “Tools for monitoring remission in rheumatoid arthritis: any will do, let's just pick one and start measuring,” Arthritis Research and Therapy, vol. 15, no. 1, article 104, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Aletaha, T. Neogi, A. J. Silman et al., “2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative,” Arthritis and Rheumatism, vol. 62, no. 9, pp. 2569–2581, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. F. C. Arnett, S. M. Edworthy, D. A. Bloch et al., “The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis,” Arthritis and Rheumatism, vol. 31, no. 3, pp. 315–324, 1988. View at Publisher · View at Google Scholar · View at Scopus
  10. A. G. Kvalvik, L. Lefsaker, S. Dyvik, and J. G. Brun, “Anti-tumor necrosis factor-alpha therapy in the ordinary clinical setting: three-year effectiveness in patients with rheumatoid arthritis,” Joint Bone Spine, vol. 74, no. 6, pp. 606–611, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. D. M. F. M. van der Heijde, “Radiographic imaging: the ‘gold standard’ for assessment of disease progression in rheumatoid arthritis,” Rheumatology, vol. 39, supplement 1, pp. 9–16, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Maini, E. W. St Clair, F. Breedveld et al., “Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial,” The Lancet, vol. 354, no. 9194, pp. 1932–1939, 1999. View at Publisher · View at Google Scholar · View at Scopus
  13. H. T. Ozer and Z. Ozbalkan, “Clinical efficacy of TNF-α inhibitors: an update,” International Journal of Clinical Rheumatology, vol. 5, no. 1, pp. 101–115, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. R. N. Maini, F. C. Breedveld, J. R. Kalden et al., “Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis,” Arthritis and Rheumatism, vol. 41, no. 9, pp. 1552–1563, 1998. View at Google Scholar · View at Scopus
  15. M. Feldmann and R. N. Maini, “Anti-TNF therapy, from rationale to standard of care: what lessons has it taught us?” The Journal of Immunology, vol. 185, no. 2, pp. 791–794, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. J. G. Bode, U. Albrecht, D. Häussinger, P. C. Heinrich, and F. Schaper, “Hepatic acute phase proteins—regulation by IL-6- and IL-1-type cytokines involving STAT3 and its crosstalk with NF-κB-dependent signaling,” European Journal of Cell Biology, vol. 91, no. 6-7, pp. 496–505, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Shimamoto, T. Ito, Y. Ozaki et al., “Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis,” Journal of Rheumatology, vol. 40, no. 7, pp. 1074–1081, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Ozaki, Y. Kawabe, H. Nakamura et al., “Elevated serum cytokine levels in a rheumatoid arthritis patient with large granular lymphocyte syndrome,” Rheumatology, vol. 40, no. 5, pp. 592–593, 2001. View at Publisher · View at Google Scholar
  19. G. Kleiner, A. Marcuzzi, V. Zanin, L. Monasta, and G. Zauli, “Cytokine levels in the serum of healthy subjects,” Mediators of Inflammation, vol. 2013, Article ID 434010, 6 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Page-McCaw, A. J. Ewald, and Z. Werb, “Matrix metalloproteinases and the regulation of tissue remodelling,” Nature Reviews Molecular Cell Biology, vol. 8, no. 3, pp. 221–233, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. R. Carrasco and A. Barton, “Biomarkers of outcome in rheumatoid arthritis,” Rheumatology Reports, vol. 2, no. 1, pp. 26–38, 2010. View at Publisher · View at Google Scholar
  22. A. Ban, M. Inaba, Y. Furumitsu et al., “Time-course of health status in patients with rheumatoid arthritis during the first year of treatment with infliximab,” Biomedicine and Pharmacotherapy, vol. 64, no. 2, pp. 107–112, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Huang, B. Xie, Q. Li et al., “Infliximab reduces CD147, MMP-3, and MMP-9 expression in peripheral blood monocytes in patients with active rheumatoid arthritis,” European Journal of Pharmacology, vol. 698, no. 1–3, pp. 429–434, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. S.-A. Yoo, S.-K. Kwok, and W.-U. Kim, “Proinflammatory role of vascular endothelial growth factor in the pathogenesis of rheumatoid arthritis: prospects for therapeutic intervention,” Mediators of Inflammation, vol. 2008, Article ID 129873, 6 pages, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. Z. Szekanecz and A. E. Koch, “VEGF as an activity marker in rheumatoid arthritis,” International Journal of Clinical Rheumatology, vol. 69, pp. 1172–1178, 2010. View at Google Scholar
  26. S. Konisti, S. Kiriakidis, and E. M. Paleolog, “Hypoxia—a key regulator of angiogenesis and inflammation in rheumatoid arthritis,” Nature Reviews Rheumatology, vol. 8, no. 3, pp. 153–162, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. G. Murdaca, F. Spanò, M. Miglino, and F. Puppo, “Effects of TNF-α inhibitors upon the mechanisms of action of VEGF,” Immunotherapy, vol. 5, no. 2, pp. 113–115, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Ballara, P. C. Taylor, P. Reusch et al., “Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis,” Arthritis and Rheumatism, vol. 44, no. 9, pp. 2055–2064, 2001. View at Google Scholar · View at Scopus
  29. L. Ozgonenel, E. Cetin, S. Tutun, P. Tonbaklar, H. Aral, and G. Guvenen, “The relation of serum vascular endothelial growth factor level with disease duration and activity in patients with rheumatoid arthritis,” Clinical Rheumatology, vol. 29, no. 5, pp. 473–477, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. H. R. Kim, K. W. Kim, B. M. Kim, M. L. Cho, and S. H. Lee, “The effect of vascular endothelial growth factor on osteoclastogenesis in rheumatoid arthritis,” PLoS ONE, vol. 10, no. 4, Article ID e0124909, 2015. View at Publisher · View at Google Scholar
  31. S. Kelly, M. Bombardieri, F. Humby et al., “Angiogenic gene expression and vascular density are reflected in ultrasonographic features of synovitis in early rheumatoid arthritis: an observational study,” Arthritis Research & Therapy, vol. 17, article 18, 2015. View at Publisher · View at Google Scholar